Loading...
01/11 07:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company's earnings call indicates strong financial performance, with significant revenue growth and improved margins driven by the patient affordability business. Despite some decline in plasma revenue, the overall outlook is optimistic with a promising pipeline of new programs and operational efficiencies. The Q&A section suggests positive sentiment from analysts, with inquiries focused on growth and expansion. The strategic acquisition and efficient operations further enhance prospects, leading to a positive stock price prediction.
Revenue $19.1 million, up 33% compared to the second quarter last year. The increase was driven by strong performance in the patient affordability business and the onboarding of new plasma centers.
Gross Margins 61.6%, an improvement of 870 basis points year-over-year. The improvement was attributed to operational efficiencies and growth in the patient affordability business.
Adjusted EBITDA $4.5 million, up 102% from the second quarter of 2024. The increase was due to higher revenues and operational efficiencies.
Net Income $1.4 million, up 99% from the second quarter of 2024. The growth was driven by increased revenues and improved margins.
Patient Affordability Revenue $7.75 million, up 190% year-over-year. The growth was due to increased claims processed, new program launches, and higher revenue per program.
Plasma Compensation Revenue $10.7 million, down 4.7% year-over-year. The decline was attributed to an oversupply of sourced plasma and increased collection efficiencies at the center level.
Gross Dollars Loaded to Cards Decreased 3.7% year-over-year. The decline was due to challenges in the plasma business.
Total Number of Loads Decreased 4.6% year-over-year. The decline was due to challenges in the plasma business.
Gross Spend Volume Decreased 6.3% year-over-year. The decline was due to challenges in the plasma business.
SG&A Expenses $7.2 million, up 35.4% year-over-year. The increase was due to investments in the employee base and operational growth.
Operating Expenses $10.3 million, up 38.3% year-over-year. The increase was due to investments in technology and employee base.
Unrestricted Cash $11.8 million, up $4.9 million from the first quarter of 2025. The increase was attributed to operational benefits from the Gamma acquisition.
Proprietary dynamic business rules technology (DBR): DBR operates in real time during the point-of-sale adjudication process, helping manufacturers and patients overcome tactics used by co-pay maximizers, ensuring assistance reaches patients as intended. It generates significant savings for pharmaceutical manufacturers.
Software-as-a-Service engagement platform: Introduced a donor app, plasma-specific CRM, and donor management system at the International Plasma Protein Congress. The response has been overwhelmingly positive, with discussions ongoing with plasma collectors and device manufacturers.
Patient affordability business growth: Revenue grew 190% year-over-year to $7.75 million, with revenue per program rising over 83%. The company launched 7 programs this quarter and 21 in the first half of the year, surpassing last year's pace. Exited the quarter with 97 active programs and expects 30-40 more by year-end.
Plasma compensation business: Revenue was $10.7 million, down 4.7% year-over-year but up 14.2% sequentially. The company onboarded 123 of 132 awarded plasma centers, bringing market share to approximately 50%. Plans to onboard 10-13 more centers in the second half of the year.
New patient services contact center: A state-of-the-art facility will open in Q3 to increase support capacity fourfold, ensuring scalability and high service levels for pharmaceutical companies and patients.
Gamma acquisition benefits: Operational benefits include annual cash cost savings at the high end of $4-5 million guidance. Unrestricted cash balances increased by $4.9 million from Q1.
Expansion in plasma technology solutions: The company is evolving from a payments partner to a broader technology provider with new software solutions for plasma collection.
Focus on scaling and innovation: The company is scaling efficiently to meet growing demand and expanding its presence in patient affordability and plasma with impactful solutions.
Plasma Business Revenue Decline: Revenue from the plasma business declined by 4.7% year-over-year, with revenue per plasma center also decreasing. This decline is attributed to an oversupply of sourced plasma and increased collection efficiencies at the center level, which are expected to persist through 2025.
Closure of Plasma Donation Centers: A plasma customer plans to close 22 underperforming donation centers, which could impact revenue and donor activity, although some donors may shift to nearby centers.
Upfront Costs for Plasma Center Onboarding: The company incurred significant upfront costs to onboard 123 new plasma centers, which negatively impacted gross profit margins in the short term.
Economic Pressures on Plasma Business: The plasma business faces economic pressures due to oversupply and efficiency improvements, delaying organic growth until 2026.
Increased Operating Expenses: Operating expenses increased by 38.3%, driven by higher compensation and benefits, stock-based compensation, and depreciation and amortization expenses, which could pressure profitability.
Dependence on Patient Affordability Business Growth: The company’s strong financial performance is heavily reliant on the rapid growth of its patient affordability business, which may pose a risk if growth slows or market conditions change.
Regulatory and Competitive Risks in Pharma Sector: The patient affordability business operates in a highly regulated and competitive pharmaceutical sector, which could pose challenges to sustained growth.
Patient Affordability Business Growth: The company expects continued growth in the patient affordability business well into 2026 and beyond, driven by strong demand from both new and existing clients. They plan to launch an additional 30 to 40 programs by year-end 2025 and open a new state-of-the-art patient services contact center in Q3 2025 to increase support capacity fourfold.
Plasma Compensation Business Outlook: The company anticipates onboarding an additional 10 to 13 plasma centers in the second half of 2025. Despite current headwinds in the plasma business, they expect a return to organic center-level growth starting in 2026 as the plasma collection cycle improves. They also plan to expand their value proposition with new software solutions, including a donor app, plasma-specific CRM, and donor management system.
Revenue Guidance for 2025: Paysign has raised its revenue guidance for 2025 to a range of $76.5 million to $78.5 million, reflecting year-over-year growth of 32.7% at the midpoint. Plasma is expected to account for approximately 56% of total revenue, while pharma patient affordability revenue is expected to make up approximately 40.5% of total revenue, representing over 145% year-over-year growth.
Gross Profit Margins and Operating Expenses: Full-year gross profit margins are expected to be between 61% and 62%. Operating expenses are projected to be between $41 million and $43 million, with depreciation and amortization expense of approximately $8.4 million and stock-based compensation of approximately $4.4 million.
Net Income and Adjusted EBITDA for 2025: Net income is expected to be between $6 million and $7 million for the year, or $0.10 to $0.12 per diluted share. Adjusted EBITDA is projected to be in the range of $18 million to $20 million, or $0.31 to $0.35 per diluted share.
Q3 2025 Revenue and Profit Margins: For Q3 2025, total revenue is expected to be in the range of $19.5 million to $20.5 million. Gross profit margins are projected to be approximately 59% due to the higher mix of plasma revenue and the launch of the new patient services contact center.
The selected topic was not discussed during the call.
The earnings call indicates strong growth prospects, with significant year-over-year improvements in financial metrics, increased revenue guidance, and operational efficiencies. The Q&A section supports optimism with plans for new programs and systems, despite management's lack of specific details. The raised revenue guidance and anticipated FDA approval for new systems suggest positive momentum. However, the lack of clear guidance on some metrics and confidentiality constraints slightly temper the outlook, preventing a 'Strong positive' rating.
The company's earnings call indicates strong financial performance, with significant revenue growth and improved margins driven by the patient affordability business. Despite some decline in plasma revenue, the overall outlook is optimistic with a promising pipeline of new programs and operational efficiencies. The Q&A section suggests positive sentiment from analysts, with inquiries focused on growth and expansion. The strategic acquisition and efficient operations further enhance prospects, leading to a positive stock price prediction.
The earnings report shows strong financial performance with a 41% revenue increase and a 737% net income rise. The acquisition of Gamma Innovation is expected to add significant cash flow and enhance tech capabilities. Although plasma revenue declined, pharma revenue is growing rapidly. The company's guidance indicates strong growth, and a share repurchase program is in place. However, management's refusal to provide specific future revenue targets and challenges in the plasma segment are concerns. Overall, the positive financial metrics and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
The earnings call presents mixed signals. While the company reports strong year-over-year revenue and EBITDA growth, challenges in the plasma business and operational costs pose risks. The Q&A reveals uncertainty in future revenue from new programs and the Gamma acquisition. The share repurchase program offers some positive sentiment, but concerns about regulatory pressures and economic factors balance the outlook. The lack of clear guidance on new programs and potential plasma business pressures contribute to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
